Medicago granted patent for influenza vaccine research aid
The patent, which is under number 2173886, is titled "Influenza virus-like particles (VLPs) comprising hemagglutinin produced within a plant." It will provide coverage for Medicago throughout Europe through July 2028. It was originally filed on July 11, 2008 and the final decision will be published in the European Patent Bulletin on June 26.
"The coverage offered by this patent strengthens Medicago's position as we expand the development of our influenza vaccine programs," Frederic Ors, Medicago's vice president of business development, said. "Additionally, we believe the patent enhances our IP position and further illustrates our competitive advantage with respect to the development of VLPs and other recombinant proteins in plants. In our opinion, our innovative method of rapidly producing efficacious influenza VLPs is a required technology for strengthened protection of the population against biological threats."
The recent news adds to Medicago's IP portfolio, which contains over 500 patents and patent applications in more than 45 countries.
Medicago is a clinical-stage biopharmaceutical company that develops novel vaccines and therapeutic proteins. Its vaccines and proteins are used to address varying infectious disease around the world.